Additionally, the discovery of LOF variants in APOC3 [31], encoding small apoC-III proteins that are associated with a low-risk lipid profile and fewer cardiovascular events [30,32], has emerged into trials with antisense oligonucleotides and are now approved in Europe for treating familial chylomicron syndrome patients with severe risk for pancreatitis. Here, APOC3 is linked to pancreatitis.